Group 1: Financial Performance - The company reported a revenue of 1.569 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 23.7% [1] - The profit attributable to equity shareholders was 498 million RMB, an increase of 24.6% compared to the previous year [1] - The basic earnings per share were 0.59 RMB, and an interim dividend of 0.33 RMB per share was proposed [1] Group 2: Product Performance - Sales of nephrology products grew approximately 28.0% year-on-year, with Uremic Clear Granules remaining the flagship product [1] - Sales of pediatric and women's products increased by about 17.5%, becoming the second-largest revenue contributor [1] - Sales of medical imaging contrast agents rose by approximately 22.0%, while skin products increased by 19.7% [1] - Other product categories, including liver and gallbladder series and other drugs, also saw growth rates of 4.6% and 5.4% respectively [1] Group 3: Gross Profit and Margin - The gross profit for the first half of 2025 was 1.209 billion RMB, up approximately 27.6% from 948 million RMB in the same period of 2024 [2] - The average gross margin was about 77.1%, an increase of 2.4 percentage points from 74.7% in the previous year, primarily due to a decrease in the procurement prices of Chinese medicinal materials [2]
康臣药业发布中期业绩 股东应占溢利4.98亿元 同比增加24.6% 皇牌产品尿毒清维持市场领先地位